SCHEMBL5495504

SCHEMBL5495504

O=C(Nc1ccc(F)cc1)Nc1ncc(-c2ccsc2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.47
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
CTSC P53634 2/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 2/20 0.47
TAAR1 Q96RJ0 1/20 0.47
IDH2 P48735 1/20 0.46
KDR P35968 1/20 0.45
TEK Q02763 1/20 0.45
RAB9A P51151 6/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
NPC1 O15118 4/20 0.45
LMNA P02545 2/20 0.45
MAPT P10636 3/20 0.44
HTT P42858 2/20 0.44
PSMD14 O00487 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5495932 0.84 RAB9A (0.54) PDGFRBPDGFRAKMT2AMEN1RAB9A
SCHEMBL5513136 0.75 EGFR (0.47) CNR1PDGFRBPDGFRACTSCIDH2
SCHEMBL5501205 0.75 CTSC (0.62) CTSCKMT2AMEN1RAB9ASMN1; SMN2
SCHEMBL5496471 0.73 CTSC (0.49) CNR1PDGFRBPDGFRACTSCKMT2A
SCHEMBL3070329 0.71 KMT2A (0.76) KMT2AMEN1TAAR1RAB9ASMN1; SMN2
SCHEMBL5750679 0.69 KMT2A (0.45) CNR1PDGFRBPDGFRAKMT2AMEN1
SCHEMBL5500015 0.69 CHEK2 (0.42) PDGFRACTSCKMT2AMEN1KDR
SCHEMBL5508263 0.69 CHEK2 (0.56) CTSCIKBKETBK1
SCHEMBL5499926 0.69 POLB (0.51) PDGFRBCTSCKMT2AMEN1KDR
SCHEMBL14342357 0.69 CTSC (0.46) CTSCIKBKETBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US claimed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP claimed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO claimed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
US-20070293484-A1 Thiophene Heteroaryl Amines SUGEN, INC. 2007-12-20 US disclosed
EP-1753750-A1 THIOPHENE HETEROARYL AMINES Sugen, Inc. (US) 2007-02-21 EP disclosed
WO-2005113548-A1 THIOPHENE HETEROARYL AMINES SUGEN, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293484-A1 Thiophene Heteroaryl Amines TTK, CHEK2, ABL1 CNR1 2854/4885PDGFRB 1167/4885PDGFRA 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.